Mednet Logo

Abstract

The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.

Related Questions

How do you determine the optimal duration for 1L doublet treatment in newly diagnosed High-Risk CLL?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · UCSF Health

Among patients with high-risk CLL and indications for treatment per iwCLL criteria (Hallek et al., PMID 29540348), treatment regimens can be broadly categorized into fixed-duration, MRD-guided, and indefinite therapies. Fixed-duration doublet regimens include acalabrutinib with venetoclax per the AM...

Would you offer treatment for asymptomatic CLL with WBC of ~300k or greater, high risk cytogenetics, or doubling time of 6-12 months?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

Generally, starting treatment in a CLL patient is recommended based on the iwCLL criteria (Hallek et al., PMID 29540348).There is no WBC threshold that would require to treat, but the vast majority of patients with a WBC of 300K will have other reasons to start therapy. If this would be a patient wi...

Do you use absolute WBC count or doubling time to determine whether to start treatment for early stage CLL?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Brigham and Women's Hospital

In my view, the pace of disease is a more relevant indicator of the need for treatment than any absolute WBC count. Observations over time usually make it clear when treatment is needed. Several studies have shown that early intervention is not associated with improved survival, though it must be ac...